The PREFER study:: both biphasic insulin aspart 30 twice-daily and basal-bolus using insulin detemir and insulin aspart enabled patients with type 2 diabetes to achieve HbA1c target<7.0%

被引：0

作者：

Liebl, A.

Prager, R.

Kaiser, M.

Binz, K.

Gailwitz, B.

机构：

[1] Ctr Diabet & Metabol, Dept Diabet, Bad Heilbrunn, Germany

[2] L Boltzmann Res Inst Metab Dis & Nutr, Dept Diabet, Vienna, Austria

[3] Novo Nordisk Pharm GmbH, Mainz, Germany

[4] Triemli City Hosp, Dept Diabet, Zurich, Switzerland

[5] Univ Tubingen, Dept Diabet, Tubingen, Germany

来源：

DIABETOLOGIA | 2006年 / 49卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

0998

引用

页码：610 / 611

页数：2

共 50 条

[1] Insulin detemir and insulin aspart:: a promising basal-bolus regimen for type 2 diabetes
Raslová, K
Bogoev, M
Raz, I
Leth, G
Gall, MA
Hancu, N
DIABETES RESEARCH AND CLINICAL PRACTICE, 2004, 66 (02) : 193 - 201
[2] The PREFER study: a comparison of outcomes in patients using insulin detemir once daily or twice daily in a basal bolus regimen with mealtime insulin aspart
Garber, A.
Binz, K.
Bergenstal, R.
Liebl, A.
DIABETOLOGIA, 2006, 49 : 610 - 610
[3] The PREFER study: Dosing recommendations for biphasic insulin aspart 30, insulin detemir and insulin aspart using treat-to-target titration
Gallwitz, B.
Prager, R.
Kaiser, M.
Binz, K.
Liebl, A.
DIABETOLOGIA, 2006, 49 : 611 - 612
[4] Efficacy of switching from basal-bolus insulin therapy to twice-daily insulin degludec/insulin aspart co-formulation plus insulin aspart in patients with poorly controlled type 2 diabetes
Gunes, E.
Gunes, M.
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2023, 27 (14) : 6691 - 6699
[5] Insulin degludec/insulin aspart vs biphasic insulin aspart 30 twice daily in Japanese patients with type 2 diabetes: A randomized controlled trial
Onishi, Yukiko
Yamada, Kenichi
Zacho, Jeppe
Ekelund, Jan
Iwamoto, Yasuhiko
JOURNAL OF DIABETES INVESTIGATION, 2017, 8 (02) : 210 - 217
[6] Biphasic insulin aspart 30 (BIAsp30), insulin detemir (IDet) and insulin aspart (IAsp) allow patients with type 2 diabetes to reach A1C target: The PRIEFER study
Liebl, Andreas
Prager, Rudolf
Kaiser, Marcel
Binz, Katharina
Gallwitz, Baptist
DIABETES, 2006, 55 : A123 - A123
[7] Comparison of twice-daily injection of biphasic insulin Lispro and basal-bolus therapy in insulin naive patients with type 2 diabetes
Yamada, Satoru
Masuda, Haruka
Kitaoka, Akira
Shiono, Kaoru
Atsuda, Koichiro
Irie, Junichiro
Shimada, Akira
DIABETES, 2007, 56 : A537 - A538
[8] Cost-effectiveness analysis of basal-bolus therapy of type 1 diabetes using insulin detemir plus insulin aspart versus NPH plus insulin aspart regimens
Valentine, WJ
Wittrup-Jensen, KU
Häuser, C
Roze, S
DIABETOLOGIA, 2005, 48 : A334 - A334
[9] Cost-effectiveness analysis of basal-bolus therapy of type 1 diabetes using insulin detemir plus insulin aspart versus NPH plus insulin aspart regimens
Valentine, WJ
Wittrup-Jensen, KU
Palmer, AJ
Roze, S
DIABETES, 2005, 54 : A609 - A609
[10] Multiple mealtime administration of biphasic insulin aspart 30 versus traditional basal-bolus human insulin treatment in patients with type 1 diabetes
Chen, J. -W.
Lauritzen, T.
Bojesen, A.
Christiansen, J. S.
DIABETES OBESITY & METABOLISM, 2006, 8 (06): : 682 - 689

← 1 2 3 4 5 →

The PREFER study:: both biphasic insulin aspart 30 twice-daily and basal-bolus using insulin detemir and insulin aspart enabled patients with type 2 diabetes to achieve HbA1c target&lt;7.0%

The PREFER study:: both biphasic insulin aspart 30 twice-daily and basal-bolus using insulin detemir and insulin aspart enabled patients with type 2 diabetes to achieve HbA1c target<7.0%